Cargando…

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

SIMPLE SUMMARY: Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in non-small cell lung cancer patients. These treatments are more effective the higher the expression of PD-L1 on tumor cells, reported as tumor proportion score. However, PD-L1 expression can be highly variable, dependi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamberti, Giuseppe, Sisi, Monia, Andrini, Elisa, Palladini, Arianna, Giunchi, Francesca, Lollini, Pier-Luigi, Ardizzoni, Andrea, Gelsomino, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692442/ https://www.ncbi.nlm.nih.gov/pubmed/33114576 http://dx.doi.org/10.3390/cancers12113129

Ejemplares similares

Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution
por: Di Federico, Alessandro, et al.
Publicado: (2021)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
por: Ricci, Costantino, et al.
Publicado: (2020)

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
por: De Giglio, Andrea, et al.
Publicado: (2022)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
por: Andrini, Elisa, et al.
Publicado: (2022)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

Peripheral nervous system adverse events associated with immune checkpoint inhibitors
por: Rossi, Simone, et al.
Publicado: (2023)

An Update on Appendiceal Neuroendocrine Tumors
por: Andrini, Elisa, et al.
Publicado: (2023)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
por: Ruzzi, Francesca, et al.
Publicado: (2023)

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
por: Dall’Olio, Filippo G., et al.
Publicado: (2022)

Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
por: Zappi, Arianna, et al.
Publicado: (2023)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

Modeling the competition between lung metastases and the immune system using agents
por: Pennisi, Marzio, et al.
Publicado: (2010)

Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors
por: Brighi, Nicole, et al.
Publicado: (2023)

Maintenance therapy in NSCLC: why? To whom? Which agent?
por: Novello, Silvia, et al.
Publicado: (2011)

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
por: Ricco, Gianluca, et al.
Publicado: (2021)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kjhb6fbajd0bbmf4a83mn7s2n8